Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
NCT04917484
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Neoplasm
Interventions
DRUG:
Lu-177-DOTA-Octreotide
Sponsor
Tine Gregersen, MD